Entity

Time filter

Source Type


Ait Ben Haddou E.H.,Service de Neurologie B et de Neurogenetique | Imounan F.,Service de Neurologie B et de Neurogenetique | Regragui W.,Service de Neurologie B et de Neurogenetique | Mouti O.,Immeuble 61 | And 5 more authors.
Revue Neurologique | Year: 2012

Introduction: Neurological manifestations in Behçet's disease represent between 4 to 49% of systemic manifestations and remain, in the long term, the leading cause of morbidity and mortality. Methods: Retrospective series of 40 severe Neurobehçet cases fulfilling the International Study Group criteria for Behçet's disease were consecutively recruited over a period from June 2004 to December 2010. All patients had clinical and ophthalmologic examinations; they underwent laboratory and imaging investigations. They received corticosteroids and cyclophosphamide as initial bolus of 600 mg/m2 of BSA in the 1st, 2nd, 4th, 6th and 8th day followed by a bolus of 600 mg/m2 BSA every 2 months for 2 years. Antithrombotic therapy was given to patients with cerebral deep venous thrombosis. Patient follow-up and tolerance to treatment were analyzed. Results: The average age at diagnosis was 34 ± 13 years, with a sex-ratio of 1.78. The clinical presentation was dominated by the meningoencephalitis in 48.8% of cases, cerebral deep venous thrombosis in 43.6% of cases and myelopathy in 7.7% of cases. The 40 patients receiving cyclophosphamide bolus, despite two aggravated cases, evolved positively with clinical improvement and good tolerance. Conclusion: The demographic and clinical aspects of our series are similar to those reported in the literature. In contrast to previously reported cases of a poor prognosis in severe neurobehçet's disease, our study suggests that immediate and aggressive treatment by cyclophosphamide may ameliorate the prognosis. However, a multicenter study is needed to confirm the possible efficacy of cyclophosphamide and further assess the long-term tolerance. © 2011 Elsevier Masson SAS. All rights reserved. Source


Ahbeddou N.,Service de Neurologie B et de Neurogenetique | Ait Ben Haddou E.,Service de Neurologie B et de Neurogenetique | Hammi S.,Service de Medecine Interne | Slimani C.,Service de Neurologie B et de Neurogenetique | And 3 more authors.
Revue Neurologique | Year: 2012

Strokes are the main neurological manifestation of antiphospholipid syndrome. Other clinical presentations are possible and may mimic classic symptoms of multiple sclerosis (MS). A 46-year-old woman, with a history of two miscarriages, presented four subacute neurological episodes (optic neuritis, right facial paralysis, paraparesis of the thigh, and right brachial monoparesis). Using McDonald criteria, the diagnosis of multiple sclerosis was retained. Because of the occurrence of thrombocytopenia during a final relapse, we reconsidered the diagnosis of MS. Search for antiphospholipid antibodies was positive. All clinical manifestations and complementary tests were compatible with the diagnosis of antiphospholipid syndrome associated with multiple sclerosis. Given the great similarity of clinical, radiological and biological findings in the two diseases, non-thrombotic neurological manifestations of antiphospholipid syndrome can be difficult to distinguish from MS associated with antiphospholipid syndrome. © 2011 Elsevier Masson SAS. All rights reserved. Source


Raissouni L.,Service de Neurologie B et de Neurogenetique | Aitbenhaddou E.,Service de Neurologie B et de Neurogenetique | Ahbeddou N.,Service de Neurologie B et de Neurogenetique | El Alaoui K.T.,Service de Neurologie B et de Neurogenetique | And 5 more authors.
Revue Neurologique | Year: 2011

Introduction: Central nervous system involvement is rare in Wegener granulomatosis. Stroke is the most common event suggestive of the disease. Comment: A 35-year-old woman, who was followed for rhinitis and mild asthma, described gradual decline of visual acuity in the right eye over two months, persistent nasal obstruction and fronto-orbital headache since a few weeks. She presented left hemiparesis due to a stroke, associated with exophthalmos and deficits of the optic nerve and abducens of the right eye. The otolaryngological examination found signs of crusty rhinitis and right nasal stenosis. The diagnosis of Wegener's granulomatosis was established on the basis of the clinical findings, radiological aspects and the presence of ANCA. The patient was treated by antiplatelet agents and high-dose corticosteroids associated with immunosuppressive drugs including cyclophosphamide in a monthly bolus. Discussion: This case illustrates two of the three pathogenic mechanisms that may account for central nervous system involvement in Wegener granulomatosis: vasculitis, extension by contiguity of granulomatous tissue from the nasal cavity or sinuses, and in situ formation of a granuloma into the brain parenchyma or meninges. © 2010 Elsevier Masson SAS. All rights reserved. Source

Discover hidden collaborations